MK

Manjeet Kaur

Active Director Director DIN 10603049
DIN 10603049 First appointment Apr 2024 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Apr 2024
Shareholding value •••• Premium profile

About Manjeet Kaur

Data last updated:

Manjeet Kaur is a Director at Sorbax Pharmaceuticals Private Limited (since 2024). The company operates in Pharma. Sorbax Pharmaceuticals Private Limited reported revenue of ₹6.71 Cr (FY 2025).

DIN 10603049
Primary Designation Director
Industry Pharma
First Appointment 26 Apr 2024
Oldest Company Age 6 yrs
Largest company Sorbax Pharmaceuticals Private Limited · ₹6.71 Cr (FY 2025)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director26 Apr 20242020₹6.71 Cr (FY 2025)Active

Directorship timeline

Open interactive timeline →
Sorbax Pharmaceuticals Private Limited
Premium access

Shareholding and investment profile for Manjeet Kaur

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Manjeet Kaur

Manjeet Kaur currently holds 1 directorship: Sorbax Pharmaceuticals Private Limited (Director, since 26 Apr 2024, revenue ₹6.71 Cr (FY 2025)).

Manjeet Kaur was first appointed on 26 Apr 2024 as Director at Sorbax Pharmaceuticals Private Limited.

The current boards of Manjeet Kaur's companies include Dheeraj Gangadhara Shetty (Sorbax Pharmaceuticals Private Limited), Kota Suresh Prabhu (Sorbax Pharmaceuticals Private Limited), Lalan Kumar Singh (Sorbax Pharmaceuticals Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available